Oral Non-Peptide GLP-1 Agonist
Orforglipron
An oral, small-molecule GLP-1 receptor agonist rather than an injectable peptide, studied for whether a pill can reproduce the weight-loss effect of injectable incretin therapy without the manufacturing and cold-chain burden of a peptide.
Status note: The FDA approved orforglipron as Foundayo for adults with obesity on April 1, 2026 (verified Oct 6, 2026). That is a prescription product; it is not the research-grade material this site covers.
Not available through research-peptide suppliers, and the approved prescription product is a different thing. Semaglutide is the closest injectable GLP-1 comparator in stock.
Mechanism
Activates the GLP-1 receptor through a non-peptide small molecule that survives oral administration, avoiding the enzymatic degradation that normally forces GLP-1-class compounds into injectable form. Clinical data are used to judge whether oral dosing changes the tolerability profile seen with injectable agonists.
Research focus
- Category
- Oral Non-Peptide GLP-1 Agonist
- Sequence length
- Small molecule
- Research status
- Approved analog exists
- Best for
- Oral, non-peptide GLP-1 pharmacology comparisons
Related compounds
Ready to compare pricing across the whole GLP-1 family?
Shop Core Power PeptidesReviewed by the Peptides For Weight Loss editorial team. See our editorial standards and sourcing methodology.